Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants

Detalles Bibliográficos
Autores principales: Hibma, Jennifer E., O’Gorman, Melissa, Nepal, Sunil, Pawlak, Sylvester, Ginman, Katherine, Pithavala, Yazdi K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135853/
https://www.ncbi.nlm.nih.gov/pubmed/35303141
http://dx.doi.org/10.1007/s00280-022-04421-7
_version_ 1784714054503235584
author Hibma, Jennifer E.
O’Gorman, Melissa
Nepal, Sunil
Pawlak, Sylvester
Ginman, Katherine
Pithavala, Yazdi K.
author_facet Hibma, Jennifer E.
O’Gorman, Melissa
Nepal, Sunil
Pawlak, Sylvester
Ginman, Katherine
Pithavala, Yazdi K.
author_sort Hibma, Jennifer E.
collection PubMed
description
format Online
Article
Text
id pubmed-9135853
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-91358532022-05-28 Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants Hibma, Jennifer E. O’Gorman, Melissa Nepal, Sunil Pawlak, Sylvester Ginman, Katherine Pithavala, Yazdi K. Cancer Chemother Pharmacol Correction Springer Berlin Heidelberg 2022-03-18 2022 /pmc/articles/PMC9135853/ /pubmed/35303141 http://dx.doi.org/10.1007/s00280-022-04421-7 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correction
Hibma, Jennifer E.
O’Gorman, Melissa
Nepal, Sunil
Pawlak, Sylvester
Ginman, Katherine
Pithavala, Yazdi K.
Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
title Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
title_full Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
title_fullStr Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
title_full_unstemmed Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
title_short Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
title_sort correction to: evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ros oncogene 1 kinase inhibitor lorlatinib in healthy participants
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135853/
https://www.ncbi.nlm.nih.gov/pubmed/35303141
http://dx.doi.org/10.1007/s00280-022-04421-7
work_keys_str_mv AT hibmajennifere correctiontoevaluationoftheabsoluteoralbioavailabilityoftheanaplasticlymphomakinasecrosoncogene1kinaseinhibitorlorlatinibinhealthyparticipants
AT ogormanmelissa correctiontoevaluationoftheabsoluteoralbioavailabilityoftheanaplasticlymphomakinasecrosoncogene1kinaseinhibitorlorlatinibinhealthyparticipants
AT nepalsunil correctiontoevaluationoftheabsoluteoralbioavailabilityoftheanaplasticlymphomakinasecrosoncogene1kinaseinhibitorlorlatinibinhealthyparticipants
AT pawlaksylvester correctiontoevaluationoftheabsoluteoralbioavailabilityoftheanaplasticlymphomakinasecrosoncogene1kinaseinhibitorlorlatinibinhealthyparticipants
AT ginmankatherine correctiontoevaluationoftheabsoluteoralbioavailabilityoftheanaplasticlymphomakinasecrosoncogene1kinaseinhibitorlorlatinibinhealthyparticipants
AT pithavalayazdik correctiontoevaluationoftheabsoluteoralbioavailabilityoftheanaplasticlymphomakinasecrosoncogene1kinaseinhibitorlorlatinibinhealthyparticipants

Ejemplares similares